Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jalaa Zarroug

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
The Israel Medical Association Journal : IMAJ|December 16, 2015
Multiple Oleomas Presenting as DermatomyositisJalaa Zarroug, Graham R V Hughes, Christopher J Edwards
Autoimmunity Reviews|March 13, 2016
Are there dangers in biologic dose reduction strategies?Christopher K Y Chan, Christopher R Holroyd, Alice Mason, et al.
Journal of Foot and Ankle Research|August 4, 2016
A pilot investigation of the prevalence of US-detectable forefoot joint pathology and reported foot-related disability in participants with systemic lupus erythematosusSandeep Mukherjee, Lindsey Cherry, Jalaa Zarroug, et al.
Clinical and Experimental Rheumatology|January 22, 2018
Switching to biosimilar infliximab: real world data in patients with severe inflammatory arthritisChristopher R Holroyd, Lucy Parker, Sarah Bennett, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
The Israel Medical Association Journal : IMAJ|December 16, 2015
Multiple Oleomas Presenting as DermatomyositisJalaa Zarroug, Graham R V Hughes, Christopher J Edwards
Autoimmunity Reviews|March 13, 2016
Are there dangers in biologic dose reduction strategies?Christopher K Y Chan, Christopher R Holroyd, Alice Mason, et al.
Journal of Foot and Ankle Research|August 4, 2016
A pilot investigation of the prevalence of US-detectable forefoot joint pathology and reported foot-related disability in participants with systemic lupus erythematosusSandeep Mukherjee, Lindsey Cherry, Jalaa Zarroug, et al.
Clinical and Experimental Rheumatology|January 22, 2018
Switching to biosimilar infliximab: real world data in patients with severe inflammatory arthritisChristopher R Holroyd, Lucy Parker, Sarah Bennett, et al.
Pageof 1